FDA approved an Investigational New Drug (IND) application for Naronapride to treat PPI-non-responsive symptomatic gastroesophageal reflux disease (GERD) .
Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic, which works by modulating two validated targets on the luminal surface of the intestinal wall, 5-HT4 receptor agonism and D2 receptor antagonism, with a well-differentiated pharmaceutical, pharmacokinetics, safety, and efficacy profile from other 5-HT4 agonists.